Takeda Oncology

SonALAsense Welcomes Dr. Ely Benaim as Chief Medical Officer and Executive Vice President of Development

Retrieved on: 
Tuesday, May 9, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Data management, Amgen, Drug development, Diffuse intrinsic pontine glioma, Jude the Apostle, History, Doctor of Philosophy, Glioblastoma, High-intensity focused ultrasound, DIPG, Journal, Patient, ALA, Reactive oxygen species, Takeda Oncology, Journal of Neuro-Oncology, Decompression (diving), Sonodynamic therapy, Aminolevulinic acid, FDA, SDT, Safety, Medical imaging, Nursing, Pharmaceutical industry, Medical device, Development

SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001 in combination with Insightec’s MR-guided focused ultrasound (MRgFUS), has appointed Ely Benaim, M.D., as Chief Medical Officer and Executive Vice President of Development.

Key Points: 
  • SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001 in combination with Insightec’s MR-guided focused ultrasound (MRgFUS), has appointed Ely Benaim, M.D., as Chief Medical Officer and Executive Vice President of Development.
  • Benaim brings decades of clinical and industry experience and incredible insights to SonALAsense,” said Mark de Souza, PhD, Chief Executive Officer at SonALAsense.
  • Later, he moved into drug development, taking high-profile positions at Amgen, Sangamo BioSciences, Millennium Pharmaceuticals, Rexahn Pharmaceuticals and others.
  • Prior to joining SonALAsense, he was Chief Medical Officer for Novocure, where he managed several pivotal clinical trials.

Amphista Therapeutics Expands Senior Team and Announces Appointment of Louise Modis as Chief Scientific Officer and Ian Churcher as Chief Technology Officer

Retrieved on: 
Tuesday, May 2, 2023
GSK, GSK plc, Therapy, EMBL, CSO, TPD, Doctor of Philosophy, Boehringer Ingelheim, Amphisbaena, Takeda Oncology, Drug discovery, Pharmaceutical industry

CAMBRIDGE, England, May 2, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD), today announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer (CSO) and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer (CTO).

Key Points: 
  • CAMBRIDGE, England, May 2, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD), today announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer (CSO) and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer (CTO).
  • In light of this, we are expanding our senior team with the appointment of Louise.
  • Ian said, "The rapid scientific progress we have made means it is the right time to broaden our senior team.
  • I am looking forward to working with Louise as we continue to develop our technology platform and in parallel build our pipeline."

Amphista Therapeutics Expands Senior Team and Announces Appointment of Louise Modis as Chief Scientific Officer and Ian Churcher as Chief Technology Officer

Retrieved on: 
Tuesday, May 2, 2023
GSK, GSK plc, Therapy, EMBL, CSO, TPD, Doctor of Philosophy, Boehringer Ingelheim, Amphisbaena, Takeda Oncology, Drug discovery, Pharmaceutical industry

CAMBRIDGE, England, May 2, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD), today announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer (CSO) and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer (CTO).

Key Points: 
  • CAMBRIDGE, England, May 2, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD), today announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer (CSO) and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer (CTO).
  • In light of this, we are expanding our senior team with the appointment of Louise.
  • Ian said, "The rapid scientific progress we have made means it is the right time to broaden our senior team.
  • I am looking forward to working with Louise as we continue to develop our technology platform and in parallel build our pipeline."

Michael Blackton Appointed as Senior Vice President of Elektrofi’s Technical Operations as Elektrofi Continues to Bolster Leadership Bench with Industry Veterans

Retrieved on: 
Thursday, April 13, 2023
Partnership, University, Senior, Value chain, Culture, San Diego, Science, Business administration, Patient, Takeda Oncology, Cell, Entrepreneurship, Master of Business Administration, Therapy, Blackton, University of California, San Diego, Management, Pharmaceutical industry, New York University, Quality

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Today Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, welcomed Michael Blackton as the company’s Senior Vice President of Technical Operations.

Key Points: 
  • BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Today Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, welcomed Michael Blackton as the company’s Senior Vice President of Technical Operations.
  • Blackton will be a member of Elektrofi’s Senior Leadership Team, responsible for Manufacturing, Technical Operations, Global Supply Chain, and Quality for Elektrofi’s growing portfolio of diverse molecules.
  • As a seasoned leader, Michael is well positioned to ensure the ongoing successful development of partnered programs.
  • Michael is a co-contributor to the publication of several PDA Technical Reports relating to operations, product development, and lifecycle practices.

One Community, One Question: What Is Your #MYelomaSTORY?

Retrieved on: 
Thursday, April 6, 2023
GSK, Wellness, MSN, MAM, International Myeloma Foundation, Regeneron Pharmaceuticals, Multiple myeloma, Social media, Hope, Bristol Myers Squibb, Marketing, Movement, Mindfulness, Organization, Takeda Oncology, Janssen Pharmaceuticals, Patient, AbbVie, Sanofi, RN, Diagnosis, Johnson & Johnson, Empathy, Region, Binding site, Wall, FAAN, IMF, Disease, Cryptocurrency, Online shopping, Food industry, Nursing, Pfizer

Messages of hope and resilience resonated across the global myeloma community—clearly showing that myeloma has no borders,” said IMF VP of Marketing Peter Anton.

Key Points: 
  • Messages of hope and resilience resonated across the global myeloma community—clearly showing that myeloma has no borders,” said IMF VP of Marketing Peter Anton.
  • Overwhelming participation in IMF in-person events: the Regional Community Workshop in San Diego, CA, and Patient Family Seminar in Boca Raton.
  • The IMF 31-Day Wellness Challenge where over 40 Support Groups logged over 45,000 minutes of movement, mindfulness, and self-care.
  • An abundance of shared snapshots from members of the myeloma community using the MAM website photo uploader.

Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership

Retrieved on: 
Monday, April 3, 2023
Therapy, Senior, Marketing, Hematology, Global Commercial Credit, Research, AstraZeneca, ARVN, Takeda Oncology, Patient, Executive Committee, Gaius Papirius Carbo Arvina, R, Nursing, Pharmaceutical industry, HAVEN, Pfizer

NEW HAVEN, Conn., April 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kelly Page has joined the company as Senior Vice President, Global Head of Oncology Strategy and Program Leadership.

Key Points: 
  • NEW HAVEN, Conn., April 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kelly Page has joined the company as Senior Vice President, Global Head of Oncology Strategy and Program Leadership.
  • “Kelly brings significant experience in the development of new oncology therapies from R&D through commercialization," said John Houston, Ph.D., Arvinas President and Chief Executive Officer.
  • Page has over 25 years of global pharmaceutical industry experience from the research setting through global commercialization, with nearly 20 years of experience in oncology therapeutics.
  • Page has also held leadership positions of increasing responsibility at companies including Takeda Oncology and Pfizer.

Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

Retrieved on: 
Monday, March 6, 2023
ADC, Multiple myeloma, Bone marrow, MBA, AstraZeneca, Transforming growth factor beta, TGF, Takeda Oncology, Kidney, Durvalumab, Drug discovery, Mab, California Pacific Medical Center, Pfizer, Compugen (company), Carcinoma, University, Strategic planning, University of California, San Diego Performance-Based Skills Assessment, Peking Union Medical College Hospital, SAN, Axitinib, Pharmaceutical industry, BeiGene, Corbus

NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors.

Key Points: 
  • NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors.
  • "Dr. Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our Board," said Alan Holmer, Chairman of the Board of Directors of Corbus.
  • Dr. Ben received his medical degree from Norman Bethune College of Medicine and his MBA from the University of California, San Diego.
  • "I look forward to working with the talented Corbus team to develop CRB-701 and CRB-601 and realize their potential."

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Retrieved on: 
Monday, February 27, 2023
Alcon, Therapy, University, Tufts University, Bachelor of Science, MBA, Chemical Corps, Chemistry, University of California, Berkeley, Sinusitis, LYRA, Patient, Doctor of Philosophy, Laboratory, CMC, Employment, CRS, Novo Nordisk, United States Department of the Army, Takeda Oncology, Pharmaceutical industry, Northeastern University, Takeda, Forma, Science, Lyra

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced the appointment of John Bishop, Ph.D., as Chief Technology Officer, effective February 27, 2023.

Key Points: 
  • WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced the appointment of John Bishop, Ph.D., as Chief Technology Officer, effective February 27, 2023.
  • “We are pleased to welcome Dr. Bishop to Lyra as we advance our in-house manufacturing systems for our proprietary drug-eluting matrix from clinical to commercial stage,” said Maria Palasis, Ph.D., Chief Executive Officer of Lyra.
  • “The manufacturing capabilities of Lyra, which uniquely combine drug quality systems with device manufacturing operations, are impressive.
  • He joins Lyra from Forma Therapeutics (acquired by Novo Nordisk), where he was Chief Technology Officer.

International Myeloma Foundation (IMF) Launches #MYelomaSTORY Campaign for Myeloma Action Month in March 2023

Retrieved on: 
Thursday, February 23, 2023
Social media, Public service announcement, GSK, PSA, Amgen, International Myeloma Foundation, MSN, Disease, RN, Multiple myeloma, Research, Regeneron Pharmaceuticals, FAAN, Q&A, Patient, Radio, Support group, Education, Movement, IMF, Sanofi, African Americans, MAM, Binding site, Bristol Myers Squibb, Takeda Oncology, Cryptocurrency, Management, Communications satellite, Tourism, Nursing, Pfizer

STUDIO CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action Month is held every year for the whole month of March to encourage individuals and groups to take actions that positively impact the myeloma community.

Key Points: 
  • STUDIO CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action Month is held every year for the whole month of March to encourage individuals and groups to take actions that positively impact the myeloma community.
  • The IMF will engage the global myeloma community by sharing stories about members of the myeloma community who live well with myeloma and by prompting others to share their stories.
  • Using the #MYelomaSTORY hashtag, all related posts will be displayed on the IMF’s digital “Wall of Stories” at the Myeloma Action Month website: mam.myeloma.org.
  • This year during March Action Month we work together, take accountability, in increase the visibility of Myeloma and take action through your #MYelomaSTORY and whole wellness within ourselves.

Toragen, Inc. Announces Appointment of Chief Scientific Officer

Retrieved on: 
Wednesday, February 8, 2023
Oncology, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Portola Pharmaceuticals, Cancer, Therapy, Takeda Oncology, Doctor of Philosophy, MD, Pharmaceutical industry

Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief Scientific Officer.

Key Points: 
  • Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief Scientific Officer.
  • Dr. Lumpkin joined Toragen in late 2018 as a consultant and became a fulltime employee in mid-2022.
  • Sandra Coufal, MD, Toragen’s CEO said, “We are thrilled to have Rick as our Chief Scientific Officer as he brings over 30 years of significant experience in early-stage biotechnology companies and synthetic chemistry.
  • Additionally, Dr. Lumpkin brings experience from COR Therapeutics, Ribogene, Amylin and Corvas International, Inc.